Celltrion Pharm, Inc. (KOSDAQ:068760)

South Korea flag South Korea · Delayed Price · Currency is KRW
71,800
-1,100 (-1.51%)
Feb 27, 2026, 3:30 PM KST
30.08%
Market Cap 3.12T
Revenue (ttm) 274.73B
Net Income (ttm) 26.03B
Shares Out 43.50M
EPS (ttm) 583.36
PE Ratio 123.08
Forward PE n/a
Dividend 200.00 (0.28%)
Ex-Dividend Date Dec 29, 2025
Volume 105,843
Average Volume 208,458
Open 72,000
Previous Close 72,900
Day's Range 71,200 - 72,800
52-Week Range 43,627 - 78,300
Beta 1.13
RSI 53.89
Earnings Date n/a

About Celltrion Pharm

Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals and general pharmacies. Celltrion Pharm Inc. was founded in 1976 and is based in Cheongju-si, South Korea. Celltrion Pharm, Inc. (KOSDAQ:A068760) operat... [Read more]

Sector Healthcare
Founded 1976
Employees 328
Stock Exchange KOSDAQ
Ticker Symbol 068760
Full Company Profile

Financial Performance

In 2020, Celltrion Pharm's revenue was 233.57 billion, an increase of 34.61% compared to the previous year's 173.51 billion. Earnings were 20.94 billion, an increase of 143.42%.

Financial Statements

News

There is no news available yet.